ADCs and mRNA

IDT Australia was the first manufacturer in the Southern Hemisphere to make a COVID mRNA vaccine - achieved in three months from technical transfer of the project through to finished product.

Our strong collaboration with multiple researchers and university partners puts us at the forefront of development and manufacturing mRNA and ADCs, enabling us to deliver innovative solutions for your project requirements.

IDT Australia is the only Australian pharmaceutical manufacturer with the expertise and capacity to drive development of advanced therapies from clinical trials through to scaled up contract manufacturing including fill finish.

With a steadfast commitment to quality and compliance, we provide comprehensive support throughout the development and manufacturing process.

IDT Benefits:

• Experience: IDT has teams qualified and experienced in high potent small molecule R&D process and design. We have the ability to leverage the synthesis and upscaled volume from previously produced molecules (see our Product Catalog), or to develop novel compounds.
• Cutting Edge Technology: IDT offers Pilot Scale Purification Extraction, Recrystallization, Tangential Flow Filtration and Column Chromatography. A variety of isolation techniques and larger scales are available.
• Ability to Scale and Validate: IDT has the Commercial Scale Facilities to enable our partners to scale and validate.